Efficacy and safety of combining olodaterol Respimat^® and tiotropium HandiHaler^® in patients with COPD: results of two randomized, double-blind, active-controlled studies

References

• QaseemAWiltTJWeinbergerSEDiagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory SocietyAnn Intern Med2011155317919121810710
   PubMed Web of Science ®Google Scholar
• National Heart, Lung, and Blood Institute [homepage on the Internet]NHLBI Factbook. 4. Disease Statistics [updated 2006] Available from: http://www.nhlbi.nih.gov/about/factbook-06/chapter4data.htmAccessed March 21, 2014
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Updated 2013 [updated 2013]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdfAccessed March 5, 2014
   Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• O’DonnellDEFlügeTGerkenFEffects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPDEur Respir J200423683284015218994
   PubMed Web of Science ®Google Scholar
• MaltaisFHamiltonAMarciniukDImprovements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPDChest200512831168117816162703
   PubMed Web of Science ®Google Scholar
• KeatingGMTiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary diseaseDrugs201272227330022217233
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• FeldmanGBernsteinJAHamiltonANivensCLaForceCThe 24-hour FEV1 time profile of olodaterol once daily (QD) via Respimat® and formoterol twice daily (BID) via Aerolizer® in patients with COPD: results from two 6-week studiesChest20131444 Meeting Abstracts749A (abstract)
   Web of Science ®Google Scholar
• LangePAumannJ-LDeromEThe 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: Results from two 6-week studiesEur Respir J201342Suppl 57982s4635 (abstract)
   Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Two 48-week studiesEur Respir J201342Suppl 57146sP764 (abstract)
   Google Scholar
• FergusonGFeldmanGHofbauerPLung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studiesEur Respir J201342Suppl 575s187 (abstract)
   Google Scholar
• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• Boehringer IngelheimCo-administration of Olodaterol Respimat^® and Tiotropium Handihaler^® Available from http://clinicaltrials.gov/show/NCT1694771. Identifier: NCT1694771Accessed September 23, 2014
   Google Scholar
• Boehringer IngelheimCo-administration of Olodaterol Respimat^® and Tiotropium Handihaler^® Available from http://clinicaltrials.gov/show/NCT1696058. Identifier: NCT1696058Accessed September 23, 2014
   Google Scholar
• JonesPWBeehKMChapmanKRDecramerMMahlerDAWedzichaJAMinimal clinically important differences in pharmacological trialsAm J Respir Crit Care Med2014189325025524383418
   PubMed Web of Science ®Google Scholar
• COMBIVENT Inhalation Solution Study GroupRoutine nebulized ipratropium and albuterol together are better than either alone in COPDChest19971126151415219404747
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJ-LJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• DecramerMWedzichaJASandströmTSafety and tolerability of QVA149, glycopyrronium and tiotropium in patients with severe to very severe COPD: the SPARK studyAbstract presented at the American Thoracic Society Annual MeetingPhiladelphia PA, USAMay 17–21, 2013
   Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• MahlerDAD’UrzoABatemanEDConcurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparisonThorax20126778178822544891
   PubMed Web of Science ®Google Scholar
• KesslerRPartridgeMRMiravitllesMSymptom variability in patients with severe COPD: a pan-European cross-sectional studyEur Respir J201137226427221115606
   PubMed Web of Science ®Google Scholar
• DahlRJadayelDAlagappanVKTChenHBanerjiDEfficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON studyInt J Chron Obstruct Pulmon Dis2013850150824159259
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• DonohueJFNiewoehnerDBrooksJO’DellDChurchASafety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled studyRespir Res20141517825015176
   PubMed Web of Science ®Google Scholar
• BarnesPJCelliBRSystemic manifestations and comorbidities of COPDEur Respir J20093351165118519407051
   PubMed Web of Science ®Google Scholar